综上所述，2023-2024年全球首创性药物取得了令人瞩目的成就。小分子药物和大分子药物的类型和来源日益丰富，传统药物设计与新型生物技术的融合发展趋势愈发明显，共同为首创性药物的开发注入了强大动力。在首创性药物中，用于难治性疾病治疗的突破性疗法以及疾 ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...

Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid ...

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower ...

This rising trend mirrors the evolution of the pharmaceutical industry in terms of investment and utilisation of novel ...

During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is ...

Verseon, a pioneering company in physics- and AI-powered drug discovery, revealed that its AI technology significantly ...

GATC West Virginia played a role in a groundbreaking AI-powered analysis of a new liver cancer drug in development — an analysis that saved inestimable hours and dollars for the client. GATC West ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

The company added the law could stifle drug innovation and jeopardize patients' access to medications. Medicare won't seek to negotiate lower prices for Eli Lilly's popular diabetes drug Mounjaro ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...